Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody
Abstract Background Dysregulated production of interleukin (IL)-6 is implicated in the pathology of inflammatory bowel disease (IBD). Neutralization of IL-6 in the gut by safe probiotic bacteria may help alleviate intestinal inflammation. Here, we developed Lactococcus lactis with potent and selecti...
Furkejuvvon:
| Váldodahkkit: | , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
BMC
2022-07-01
|
| Ráidu: | Microbial Cell Factories |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1186/s12934-022-01873-7 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|